Mizuho raised the firm’s price target on Adma Biologics to $14 from $12 and keeps a Buy rating on the shares. The firm’s analysis of hyper top-line growth and profitable therapeutics comps “suggests premium multiples are warranted to reflect the scarcity value around the story” and it raised its base case and bull case targets to reflect higher confidence in existing capacity breadth and the ASCENIV mix expanding, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADMA:
- Biotech Alert: Searches spiking for these stocks today
- Adma Biologics price target raised to $10 from $8 at Raymond James
- Adma Biologics price target raised to $10 from $8 at Cantor Fitzgerald
- Adma Biologics price target raised to $12 from $10 at Mizuho
- Adma Biologics price target raised to $10 from $7.50 at H.C. Wainwright